April 30, 2021
In an upbeat earnings report today (April 30), Anglo-Swedish drugmaker AstraZeneca reported $275 million in revenue from its Covid-19 vaccine in the first three months of the year.
The vaccine, known as Vaxzevria, is one of four authorized for use against Covid-19 in the EU. It’s also been one of the more controversial ones: Many countries paused their rollout of the jab when it emerged that it can, in some rare cases, cause blood clots. AstraZeneca has also become embroiled in a public showdown with the EU over delayed supplies; the bloc is suing the company for alleged breach of contract. Meanwhile, the US has not approved the shot and plans to send most of its supply overseas.
Co-creator of AstraZeneca COVID Shot Defends Its Safety
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Africa, Malaria Vaccine
voazimbabwe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from voazimbabwe.com Daily Mail and Mail on Sunday newspapers.
Covid vaccine in the US - live updates: J&J pause lifted, side effects, locations, My Turn
as.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from as.com Daily Mail and Mail on Sunday newspapers.